Drug Profile
Research programme: Recombinant bone morphogenetic protein therapeutics - Bioventus
Latest Information Update: 28 Jul 2020
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Bioventus
- Class Bone morphogenetic proteins; Recombinant proteins
- Mechanism of Action Bone morphogenetic protein receptor modulators; Osteogenesis stimulants; Protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bone disorders; Fracture
Most Recent Events
- 28 Jul 2020 No recent reports of development identified for research development in Bone-disorders in USA
- 28 Jul 2020 No recent reports of development identified for research development in Fracture in USA
- 28 Jul 2018 No recent reports of development identified for research development in Bone-disorders in USA